Thursday, October 30, 2008 4:33:09 PM
We've all been waiting for cellulose-based ethanol to become a cost-efficient reality. CleanTech BioFuels (CLTH) is on the cutting edge of the biofuels revolution. They're using patented new technology developed at the University of California at Berkeley to efficiently produce ethanol from municipal solid waste converted into sugars from cellulosic material.
This could be a terrific ground floor opportunity; things are moving fast - this just in:
"CleanTech Biofuels Finalizes Transaction with World Waste Technologies ...
"--(USEquityNews)-- 10/29/2008 - (CLTH), formerly a sublicensee of World Waste Technologies' patent (U.S. Patent No. 6,306,248 ...), announces that it has acquired that patent. CleanTech Biofuels is now able to file new United States and international patents based on the combined technologies described in the patent and those of Biomass North America Licensing. CleanTech CEO, Ed Hennessey, noted, "We are very excited to have completed this transaction, as this acquisition creates many new opportunities for our company."
Here's some more details from a message board post:
"CleanTech has, for the first time, satisfactorily tested the technology and associated equipment for efficiently generating fermentable sugars from municipal solid waste. The patented technology uses nitric acid, versus the more common sulfuric or hydrochloric acid, for hydrolyzing cellulosic material. CleanTech believes that nitric acid hydrolysis represents the cutting edge of current technology in the cellulosic ethanol industry. These fermentable sugars can then be processed into ethanol.
"The advantages of turning waste directly into ethanol are significant:
"- It offers a non-fossil fuel source that has an already existing supplier, avoiding agricultural and food supply issues.
- It reduces pollution released into the environment by the disposal of municipal solid waste.
- It reduces the amount of material going into landfills by as much as eighty five percent.
- It generates biofuels and other usable energy products at competitive prices."
Recent CYTH News
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:46:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:45:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:44:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:43:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:42:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:41:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:40:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:44:54 PM
- Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office • Business Wire • 01/29/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:01:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:50:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:48:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:28:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:25:09 AM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:21 PM
- Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 • Business Wire • 12/18/2023 02:15:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 12/18/2023 11:02:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 11:01:44 AM
- Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 12/14/2023 09:01:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 11/30/2023 09:30:27 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM